4-Octyl Itaconate 抑制了在贝赫特尿道炎和实验性自身免疫尿道炎中促炎性细胞因子的产生
Qingfeng Wang1, Xingsheng Ye1, Shiyao Tan1
1The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, People's Republic of China.
Inflammation
|January 6, 2024
概括
4-octyl itaconate (4-OI) 通过激活NRF2信号来减少Behcet膜炎 (BU) 和实验性自身免疫膜炎 (EAU) 的炎症. 这种代谢物降低了促炎性细胞因子的调节,可能为BU提供未来的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 贝赫特卵膜炎 (BU) 和实验性自身免疫卵膜炎 (EAU) 是一种具有炎症性眼病,其特征是炎症性细胞因子的升高.
- 核因子-E2相关因子2 (NRF2) 信号在调节炎症反应中起作用.
研究的目的:
- 调查4-octyl itaconate (4-OI) 对BU和EAU的促炎细胞因子产生的抗炎作用.
- 探索NRF2信号激活在调解这些效应中的作用.
主要方法:
- 来自BU患者和健康个体的外周血液单核细胞 (PBMC) 在体外用4-OI治疗.
- 实验性自身免疫性脑膜炎 (EAU) 在小鼠体内研究中被诱导.
- 使用流式细胞计,qPCR,ELISA,西部斑点和RNA测序来评估细胞因子表达,NRF2激活和基因表达.
主要成果:
- 4-OI治疗降低了BU PBMCs中的促炎细胞因子 (IL-17,TNF-α,MCP-1,IL-6) 和Th17细胞的调节.
- 4-OI改善了EAU的严重性,减少了脏Th1/Th17细胞,并增加了小鼠的核NRF2表达.
- 4-OI降低了参与免疫反应积极调节的基因.
结论:
- 4-octyl itaconate在BU和EAU中对促炎性细胞因子的产生表现出抑制作用.
- 这些效应可能通过激活NRF2信号传递来介导.
- 4-OI显示出作为BU和相关炎症状况的治疗剂的潜力.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
01:29Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
01:29Drugs for Treatment of Ulcerative Colitis in IBD
144
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
144